Yoshiyuki Watanabe

Dr. Yoshiyuki Watanabe

Kawasaki Rinko General Hospital
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YWYoshiyuki Watanabe
Yoshiyuki Watanabe
RCRyan J Castoro
Ryan J Castoro
HKHyun Soo Kim
Hyun Soo Kim
BNBrittany North
Brittany North
RORitsuko Oikawa
Ritsuko Oikawa
JIJean-Pierre Issa
Jean-Pierre Issa
MLL3 is a histone 3- lysine 4 methyltransferase with tumor-suppressor properties that belongs to a family of chromatin regulator genes potentially altered in neoplasia. Mutations in MLL3 were found in a whole genome analysis of colorectal cancer but have not been confirmed by a separate study. We analyzed mutations of coding region and promoter methylation in MLL3 using 126 cases of colorectal cancer. We found two isoforms of MLL3 and DNA sequencing revealed frameshift and other mutations affecting both isoforms of MLL3 in colorectal cancer cells and 19 of 134 (14%) primary colorectal samples analyzed. Moreover, frameshift mutations were more common in cases with microsatellite instability (31%) both in CRC cell lines and primary tumors. The largest isoform of MLL3 is transcribed from a CpG island-associated promoter that has highly homology with a pseudo-gene on chromosome 22 (psiTPTE22). Using an assay which measured both loci simultaneously we found prominent age related methylation in normal colon (from 21% in individuals less than 25 years old to 56% in individuals older than 70, R = 0.88, p<0.001) and frequent hypermethylation (83%) in both CRC cell lines and primary tumors. We next studied the two loci separately and found that age and cancer related methylation was solely a property of the pseudogene CpG island and that the MLL3 loci was unmethylated. We found that frameshift mutations of MLL3 in both CRC cells and primary tumor that were more common in cases with microsatellite instability. Moreover, we have shown CpG island-associated promoter of MLL3 gene has no DNA methylation in CRC cells but also primary tumor and normal colon, and this region has a highly homologous of pseudo gene (psiTPTE22) that was age relate DNA methylation.

1 January 2012 in World Journal of Gastroenterology
Verified
Journal Article
Open access
SIShinya Ishigooka
Shinya Ishigooka
MNMasahito Nomoto
Masahito Nomoto
NONobuyuki Obinata
Nobuyuki Obinata
YOYoshichika Oishi
Yoshichika Oishi
YSYoshinori Sato
Yoshinori Sato
FIFumio Itoh
Fumio Itoh
Evaluation of magnifying colonoscopy in the diagnosis of serrated polyps

7 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
HYHiroyuki Yamamoto
Hiroyuki Yamamoto
YWYoshiyuki Watanabe
Yoshiyuki Watanabe
YSYoshinori Sato
Yoshinori Sato
TMTadateru Maehata
Tadateru Maehata
FIFumio Itoh
Fumio Itoh
Gastric cancer (GC) is a significant source of global cancer death with a high mortality rate, because the majority of patients with GC are diagnosed at a late stage, with limited therapeutic choices and poor outcomes. Therefore, development of minimally invasive or noninvasive biomarkers which are specific to GC is crucially needed. The latest advancements in the understanding of GC molecular landscapes and molecular biological methods have accelerated attempts to diagnose GC at an early stage. Body fluids, including peripheral blood, saliva, gastric juice/wash, urine, and others, can be a source of biomarkers, offering new methods for the early detection of GC. Liquid biopsy-based methods using circulating sources of cancer nucleic acids could also be considered as alternative strategies. Moreover, investigating gastric juices/washes could represent an alternative for the detection of GC via invasive biopsy. This review summarizes recently reported biomarkers based on DNA methylation, microRNA, long noncoding RNA, circular RNA, or extracellular vesicles (exosomes) for the detection of GC. Although the majority of studies have been conducted to detect these alterations in advanced-stage GC and only a few in population studies or early-stage GC, some biomarkers are potentially valuable for the development of novel approaches for an early noninvasive detection of GC.

8 December 2011 in Tumor Biology
Verified
Journal Article
Closed access
PDF file
YOYoshichika Oishi
Yoshichika Oishi
YWYoshiyuki Watanabe
Yoshiyuki Watanabe
YYYoshihito Yoshida
Yoshihito Yoshida
YSYoshinori Sato
Yoshinori Sato
THTetsuya Hiraishi
Tetsuya Hiraishi
FIFumio Itoh
Fumio Itoh

20 October 2022 in Helicobacter
Verified
Journal Article
Open access
MTMomoko Tsuda
Momoko Tsuda
YWYoshiyuki Watanabe
Yoshiyuki Watanabe
RORitsuko Oikawa
Ritsuko Oikawa
RWRyosuke Watanabe
Ryosuke Watanabe
MHMasayuki Higashino
Masayuki Higashino
MKMototsugu Kato
Mototsugu Kato
Background: Although there are many Helicobacter pylori (H. pylori) diagnostic methods, the culture and antibiotic susceptibility test is an important method for selecting the most effective H. pylori eradication regimen. However, this diagnostic method is complicated and takes several days; therefore, the development of a rapid and simple diagnostic method is required. Eradication failure due to clarithromycin (CAM) resistance should also be considered. In this study, we report the clinical evaluation of point‐of‐care testing (POCT) kit using intragastric fluid, a novel kit for detecting H. pylori and CAM resistance.Materials and Methods: The study participants were 143 patients suspected of H. pylori infection and had an endoscopic examination. The novel diagnostic kit diagnosed H. pylori infection and CAM resistance‐associated mutation using intragastric fluid. To diagnose H. pylori infection, the relationship between the diagnostic kit and conventional diagnostic methods (urea breath test, stool antigen test, culture test, and real‐time polymerase chain reaction [PCR]) was evaluated. For CAM resistance‐associated mutation detection, the concordance between the diagnostic kit and antibiotic susceptibility test was evaluated.Results: The diagnosis of H. pylori infection with the novel molecular diagnostic kit using intragastric fluid showed significant relationship with conventional diagnostic methods. Especially when the culture was control, the sensitivity was 100% (67/67), the specificity was 95.9% (71/74), and the overall concordance was 97.9% (138/141). The detection of CAM resistance‐associated mutations had a concordance rate of 97.0% (65/67) when compared with the antibiotic susceptibility test.Conclusions: The H. pylori molecular POCT kit uses intragastric fluid as a sample and can diagnose H. pylori infection and detect CAM resistance‐associated mutations within an hour. This novel kit is expected to prove useful in selecting the most effective eradication regimen for H. pylori.

18 September 2006 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
YWYoshiyuki Watanabe
Yoshiyuki Watanabe
NKNaoyuki Kato
Naoyuki Kato
TMTadateru Maehata
Tadateru Maehata
MOMasaru Okamoto
Masaru Okamoto
TTTakashi Tsuda
Takashi Tsuda
FIFumio Itoh
Fumio Itoh